Alzheimer’s Disease

Phase II clinical trial of SAGE-718 for the treatment of MCI and early AD

Phase II trial of XPro1595 for the treatment of Alzheimer’s disease

Targeting cellular senescence in tauopathies

Viral-mediated gene therapy for neurodegenerative disease

Improving the precision and safety of CRISPR/Cas genome editing

Screening for delirium in individuals with dementia

Targeting neuroinflammation: identifying new targets using transcriptomics

Developing novel digital biomarkers

Biomarkers of delirium incidence and severity

Successful Aging after Elective Surgery: goals of the SAGES II study

State of microglial and inflammatory markers in the AD field

Biomarkers for risk assessment and early diagnosis of AD

How does exercise affect cognition?

Next steps in dementia biomarkers

The neurogenesis hypothesis: NA-831 for the treatment of Alzheimer’s disease

Poor outcomes in delirium superimposed on dementia